pSivida Corp. (PSDV) insider have most recently took part in a trading activity. On Jun 14, 2017 Lurker Nancy, President and CEO bought 56,700 shares having total worth of $99,792 at the price of $1.76 per share, following the transaction a total of 56,700 shares owned by Lurker Nancy.
Shares of pSivida Corp. (PSDV) traded down 15.87% on Jun 13, 2017, hitting $1.75. 6,074,997 shares of the company’s stock traded hands. pSivida Corp. has a 52 week low of $1.56 and a 52 week high of $4.82. The company’s market cap is $110 million.
pSivida Corp. (PSDV) last announced its earnings results on May 4, 2017. The company reported -0.15 earnings per share (EPS) for the quarter, same as the consensus estimate of -0.15. The company had revenue of $1 million for the quarter, compared to the consensus estimate of $0 million. During the same quarter in the previous year, the company posted -0.15 earnings per share. The company’s revenue for the quarter was up 82% on a year-over-year basis.
|earnings per share||-0.15||-0.16||-0.21||-0.19||-0.15||-0.18||-0.17||-0.17||-0.17||-0.14|
PSivida Corp. was organized as a Delaware Corporation in March 2008. On June 19, 2008, it reincorporated from Western Australia to the United States. The company develops tiny, sustained-release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. It is focused on treatment of chronic diseases of the back of the eye utilizing its core technology platforms, Durasert and BioSilicon. It currently has three approved products and two principal product candidates under development, which represent successive generations of its Durasert technology platform. It have developed three of the four sustained release devices for treatment of retinal diseases currently approved in the U.S. or the European Union (EU). Its most recently approved product, ILUVIEN, is an injectable, sustained-release micro-insert delivering the corticosteroid fluocinolone acetonide (FAc) over a period of up to 3 years for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. ILUVIEN is being developed by its licensee Alimera Sciences, Inc. (Alimera). ILUVIEN has received marketing authorization in the United Kingdom, Austria, France, Germany and Portugal, and marketing authorization is pending in Italy and Spain. The International Diabetes Federation has estimated that approximately 19.1 million people in these seven countries have diabetes, of which Alimera has estimated that approximately 1.1 million suffer from vision loss associated with DME. Alimera has announced its intention to proceed with the direct commercialization of ILUVIEN in Germany, the U.K. and France in 2013. It is pursuing the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (posterior uveitis) as another indication for the same injectable micro-insert used in ILUVIEN. It did not license this indication to Alimera. It are also developing a bioerodible, injectable micro-insert delivering latanoprost (the Latanoprost Product) to treat glaucoma and ocular hypertension. Its primary technology systems are Durasert and BioSilicon.
Latest posts by William White (see all)
- Insider Trading Review: FS Investment Corporation $FSIC - January 13, 2018
- Insider Trader Watch: ENERTOPIA CORP $ENRT - January 13, 2018
- Insider Trading in Focus: Swiss Helvetia Fund, Inc. (The) $SWZ - January 13, 2018